Paula González Villarroel

Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis

Ana Fernández Montés, Paula González Villarroel, Manuel Valladares Ayerbes et al. · Journal of Cancer Research and Therapeutics · 2017 · 24 citations · Full text

Megestrol acetate-induced adrenal insufficiency

Paula González Villarroel, Isaura Fernández Pérez, Concepción Páramo et al. · Clinical & Translational Oncology · 2008 · 18 citations · Full text

Adrenal Gland, Physiology, Pharmacotherapy +4

Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram

Ana Fernández Montés, Francisca Rivera, Nieves Martínez Lago et al. · Clinical & Translational Oncology · 2019 · 15 citations

Oncology, Cancer Management, Colorectal Cancer +7

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

Ana Fernández Montés, Nieves Martínez Lago, J. de la Cámara Gómez et al. · Annals of Oncology · 2019 · 15 citations · Full text

Second-line Treatment, Type Ras, Oncology +8

Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

Ana Fernández Montés, Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca et al. · Scientific Reports · 2021 · 12 citations · Full text